Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The effects of hypertension as an existing comorbidity on mortality rate in patients with COVID-19 A systematic review and meta-analysis

View ORCID ProfileElena Whiteman
doi: https://doi.org/10.1101/2020.11.16.20149377
Elena Whiteman
Warwick Medical School, University of Warwick, Medical School Building, Coventry, CV4 7HL
Roles: Medical Student
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elena Whiteman
  • For correspondence: elena.whiteman@warwick.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Coronavirus has spread throughout the world rapidly, and there is a growing need to identify host risk factors to identify those most at risk. There is a growing body of evidence suggesting a close link exists between an increased risk of infection and an increased severity of lung injury and mortality, in patients infected with COVID-19 who have existing hypertension. This is thought to be due to the possible involvement of the virus target receptor, ACE2, in the renin-angiotensin-aldosterone blood pressure management system.

Objective To investigate the association between hypertension as an existing comorbidity and mortality in hospitalized patients with confirmed coronavirus disease 2019 (COVID-19).

Methods A systematic literature search in several databases was performed to identify studies that comment on hypertension as an existing comorbidity, and its effect on mortality in hospitalized patients with confirmed COVID-19 infection. The results of these studies were then pooled, and a meta-analysis was peformed to assess the overall effect of hypertension as an existing comorbidity on risk of mortality in hospitalized COVID-19 positive patients.

Results A total of 12243 hospitalised patients were pooled from 19 studies. All studies demonstrated a higher fatality rate in hypertensive COVID-19 patients when compared to non-hypertensive patients. Meta-analysis of the pooled studies also demonstrated that hypertension was associated with increased mortality in hospitalized patients with confirmed COVID-19 infection (risk ratio (RR) 2.57 (95% confidence interval (CI) 2.10, 3.14), p < 0.001; I2 =74.98%).

Conclusion Hypertension is associated with 157% increased risk of mortality in hospitalized COVID-19 positive patients. These results have not been adjusted for age, and a meta-regression of covariates including age is required to make these findings more conclusive.

Summary Risk of mortality is considerably higher in hospitalised COVID-19 patients who have hypertension as an existing comorbidity prior to admission.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding was required

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data that is relevant to this research is available within the main text or supplementary material

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted November 17, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The effects of hypertension as an existing comorbidity on mortality rate in patients with COVID-19 A systematic review and meta-analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The effects of hypertension as an existing comorbidity on mortality rate in patients with COVID-19 A systematic review and meta-analysis
Elena Whiteman
medRxiv 2020.11.16.20149377; doi: https://doi.org/10.1101/2020.11.16.20149377
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
The effects of hypertension as an existing comorbidity on mortality rate in patients with COVID-19 A systematic review and meta-analysis
Elena Whiteman
medRxiv 2020.11.16.20149377; doi: https://doi.org/10.1101/2020.11.16.20149377

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (409)
  • Dentistry and Oral Medicine (68)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4817)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (188)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5284)
  • Intensive Care and Critical Care Medicine (327)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (112)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (203)
  • Oncology (439)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (128)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (771)
  • Public and Global Health (1800)
  • Radiology and Imaging (322)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)